by Elec23 | Oct 22, 2025 | News&events
VisMederi continues to strengthen its engagement in metapneumovirus control and vaccine research, confirming its active role in the international scientific community. At the 10th ESWI Influenza Conference, held in Valencia from 20 to 23 October 2025, Maria Giovanna...
by Elec23 | Oct 16, 2025 | News&events
VisMederi’s Cell Mediated Immunity (CMI) Team members, Ilaria Razzano and Ilaria Ferrigno, traveled to Sofia to deliver a training session at Hera Medical Center. The focus of the training was on PBMC (Peripheral Blood Mononuclear Cells) isolation from clinical...
by Elec23 | May 30, 2025 | News&events
Influenza has been a major global problem for centuries. Although vaccination can reduce the health and economic consequences of an influenza epidemic, current vaccines are far from perfect. Many research teams around the world have worked to create an effective...
by Elec23 | Apr 11, 2025 | News&events
We are proud to announce that VisMederi has once again been included in the Financial Times FT 1000 ranking, placing 483rd among Europe’s fastest-growing companies in 2025. The eighth annual list, compiled in collaboration with Statista, recognises companies that have...
by Elec23 | Apr 9, 2025 | News&events
VisMederi’s R&D Department, in collaboration with the University of Siena, University of Palermo, and University of Bari, has developed and validated a new high-throughput neutralization assay for human Metapneumovirus (hMPV) A and B. This pivotal work aims to...
